ANIK Anika Therapeutics Inc.

Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the 18th bi-annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy (ESSKA) Congress, being held in Glasgow, Scotland on May 9-12, 2018.

“We look forward to showcasing our pioneering orthopedic and regenerative medicine solutions, including CINGAL and HYALOFAST, at the 18th ESSKA Congress,” said Joseph Darling, President and CEO, Anika Therapeutics. “Our participation represents an important opportunity to highlight real-world evidence from CINGAL and HYALOFAST to the 4,000 medical experts in the field of sports traumatology, knee surgery and arthroscopy participating from all over the world.”

Company-Sponsored Physician Education

Location: Anika Booth #51, Hall no.4, Scottish Event Campus

Wednesday, May 9, 2018

  • 10:00 - 11:00 Dr. Mikolaj Wrobel, OrtopediKa Clinic in Warsaw, Poland, will be available at the booth for guided training sessions with the HYALOFAST Virtual Surgical Simulator.

Thursday, May 10, 2018

  • 15:30 - 16:30 Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy, will be available at the booth for guided training sessions with the HYALOFAST Virtual Surgical Simulator.

Company-Sponsored Lunch Symposium

Location: Room Boisdale 1/2, Scottish Event Campus

Friday, May 11, 2018

  • 12:30 - 13:30 Boisdale 1/2 Room, Lunch Symposium: HYALOFAST One-step Procedure: Best Practice and New Evidence in Cartilage Repair

    Moderator: Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy

Speakers and Topics:

  • Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy: HYALOFAST Long-Term Clinical Outcomes in the Treatment of Full-Thickness Cartilage Lesions of the Knee
  • Dr. Bogusław Sadlik, St. Luke Clinic, Bielsko Biala – Poland: HYALOFAST Arthroscopic Implantation in the Knee: Pitfalls, Pearls and MRI Based Rehab Protocol
  • Prof. Stephan Nehrer, Danube University, Krems – Austria: HYALOFAST in the Treatment of Cartilage Defects in the Ankle: Surgical Technique and Clinical Results

About ESSKA Congress

The 18th ESSKA (European Society for Sports Traumatology, Knee Surgery and Arthroscopy) Congress is expected to include 4,000 medical experts in the field of sports traumatology, knee surgery and arthroscopy from all over the world. It offers many opportunities to interact with orthopedic surgeons, physio therapists and other medical professionals.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

EN
08/05/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Anika Reports Fourth Quarter and Full Year 2025 Financial Results Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain manag...

 PRESS RELEASE

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Confere...

Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference BEDFORD, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Steve Griffin, President and CEO of Anika, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on Monday, March 2, 2026 at 11:30am CT / 12:30pm ET. Management will also participate in one-on-one investor meetings throughout the event. The presentation will be webcast live on the under the Investors section of Anika Therapeuti...

 PRESS RELEASE

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on T...

Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026 BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (internat...

 PRESS RELEASE

Anika Therapeutics Announces Leadership Transition

Anika Therapeutics Announces Leadership Transition Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive OfficerCheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve) Griffin, current Executive Vice President, Chief Financial Officer and Chie...

 PRESS RELEASE

Anika Reports Third Quarter 2025 Financial Results

Anika Reports Third Quarter 2025 Financial Results Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch